Christopher Ryan Sullivan - 13 Feb 2023 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Financial Officer
Signature
/s/ Jennifer Zoltoski, by Power of Attorney
Issuer symbol
AVTX
Transactions as of
13 Feb 2023
Net transactions value
$0
Form type
4
Filing time
15 Feb 2023, 15:19:43 UTC
Previous filing
07 Oct 2022
Next filing
17 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +40,000 $0.000000 40,000 13 Feb 2023 Common Stock 40,000 $2.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each applicable vesting date.